The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis | Zendy

Vanessa Evans | Zendy; Matthew Lawrence | Zendy; Janet Whitley | Zendy; C. Johns | Zendy; Suresh Pillai | Zendy; Karl Hawkins | Zendy; Kieron Power | Zendy; Keith Morris | Zendy; P. R. Williams | Zendy; Phillip Evans | Zendy

Open Access

The treatment effect of rivaroxaban on clot characteristics in patients who present acutely with first time deep vein thrombosis

Author(s) -

Vanessa Evans,

Matthew Lawrence,

Janet Whitley,

C. Johns,

Suresh Pillai,

Karl Hawkins,

Kieron Power,

Keith Morris,

P. R. Williams,

Phillip Evans

Publication year - 2021

Publication title -

clinical hemorheology and microcirculation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 54

eISSN - 1875-8622

pISSN - 1386-0291

DOI - 10.3233/ch-201030

Subject(s) - rivaroxaban , medicine , thrombosis , deep vein , biomarker , anticoagulant , prospective cohort study , gastroenterology , surgery , atrial fibrillation , warfarin , biochemistry , chemistry

The acute vascular disease deep vein thrombosis (DVT) requires oral anticoagulants to prevent progression. Monitoring therapeutic efficacy of direct oral anticoagulants (DOAC), including rivaroxaban, is problematic as no reliable test is available. Advances in rheometry have led to the development of a functional coagulation biomarker using Gel Point (GP) analysis which assesses clot structure formation. The biomarker measures incipient clot formation time (TGP) and quantifies fibrin clot structure in terms of fractal dimension (df).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research